title: Access of children and adolescents with type 1 diabetes to insulin pump therapy has greatly increased in France since 2001.
abstract: OBJECTIVE
  Insulin pump therapy is an emerging option in the management of type 1 diabetes (T1D), but it often remains unused. For this reason, in 2007, a French national survey was carried out to update the frequency of insulin pump use in the paediatric population compared with a previous survey done in 2001.
  
  
  METHODS
  The present survey was performed in hospital departments involved in paediatric diabetes management (n = 67) and in adult departments involved in adolescent diabetes management (n = 113). The number of T1D children (age < 18 years) treated in each department, with or without the use of an insulin pump, and the number of insulin pump therapies initiated during the previous year were collected.
  
  
  RESULTS
  A total of 60 paediatric and 28 adult centres responded, involving 9073 T1D children and adolescents (93% in paediatric departments). Of these patients, 1461 (16%) were treated by insulin pump, 89% of which were managed in paediatric centres. However, pump use was more frequent in adult than in paediatric centres (32% versus 18%, respectively). Also, 38% of insulin pumps were initiated during the year prior to the survey. In addition, in 2001, 140 children were treated with insulin pump in 13 paediatric centres (versus 56 centres in 2007).
  
  
  CONCLUSIONS
  The number of centres using insulin pump therapy for diabetic children and the number of children treated by insulin pump were increased fourfold and 10-fold, respectively, from 2001 to 2007, indicating greater access to pump therapy in the French paediatric population. The present survey is still ongoing to evaluate the decision-making criteria that influence the initiation of insulin pump therapy in T1D paediatric patients.
authors.affiliation: Service de pédiatrie A, American Memorial Hospital, CHU de Reims, France. vsulmont@chu-reims.fr
authors.forename: V
authors.initials: V
authors.lastname: Sulmont
authors.forename: V
authors.initials: V
authors.lastname: Lassmann-Vague
authors.forename: B
authors.initials: B
authors.lastname: Guerci
authors.forename: H
authors.initials: H
authors.lastname: Hanaire
authors.forename: H
authors.initials: H
authors.lastname: Leblanc
authors.forename: E
authors.initials: E
authors.lastname: Leutenegger
authors.forename: M
authors.initials: M
authors.lastname: Mihaileanu
authors.forename: N
authors.initials: N
authors.lastname: Tubiana-Rufi
mesh_terms: D000328:Adult; D017677:Age Distribution; D002648:Child; D003625:Data Collection; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000453:epidemiology*; D005602:France / Q000453:epidemiology; D005843:Geography; D006297:Health Services Accessibility / Q000706:statistics & numerical data*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007328:Insulin / Q000008:administration & dosage*; D007332:Insulin Infusion Systems / Q000706:statistics & numerical data*
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin